Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice GuidelinesRichard J. Gralla, David G. Pfister, James M. Koeller et al.|Journal of Clinical Oncology|1999Cited by 670
A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the BreastLawrence J. Solin, S Badve, Robert P. Gray et al.|JNCI Journal of the National Cancer Institute|2013Cited by 523
Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and CapecitabineEdith A. Perez, Gabriel N. Hortobágyi, Guillermo Lerzo et al.|Journal of Clinical Oncology|2007Cited by 392
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, William E. Barlow et al.|Cancer Research|2021Cited by 88
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trialHao Cheng, Edith A. Perez|British Journal of Cancer|2014Cited by 32